Cargando…
Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC
Non-small cell lung cancer (NSCLC) accounts for a large proportion of cancer deaths and is characterized by low treatment response rates and poor overall prognosis. In the absence of specific treatable mutations, cisplatin-based chemotherapy plays an important role in the treatment of this disease....
Autores principales: | MacDonagh, Lauren, Gallagher, Michael F., Ffrench, Brendan, Gasch, Claudia, Breen, Eamon, Gray, Steven G., Nicholson, Siobhan, Leonard, Niamh, Ryan, Ronan, Young, Vincent, O'Leary, John J., Cuffe, Sinead, Finn, Stephen P., O'Byrne, Kenneth J., Barr, Martin P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641151/ https://www.ncbi.nlm.nih.gov/pubmed/29069808 http://dx.doi.org/10.18632/oncotarget.19881 |
Ejemplares similares
-
MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer
por: MacDonagh, Lauren, et al.
Publicado: (2021) -
Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin
por: MacDonagh, Lauren, et al.
Publicado: (2021) -
In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC
por: Heavey, Susan, et al.
Publicado: (2016) -
Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC
por: Moore, Gillian, et al.
Publicado: (2021) -
Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention
por: Ffrench, Brendan, et al.
Publicado: (2014)